Perrigo announced the sale of its infant formula business for up to $175 million, including a significant upfront cash payment. This strategic divestiture aims to streamline its portfolio and focus on its core self-care business, though it will result in a substantial non-cash impairment charge.
Perrigo is selling its infant formula business to MeridianMade for an initial $40 million cash, with potential for an additional $135 million based on future performance. This move is part of Perrigo's broader strategy to focus on its core self-care business, indicating a strategic shift towards higher-margin or more aligned operations. While the divestiture brings in cash and simplifies the business, the anticipated non-cash impairment charge of $275 million to $375 million in Q4 2026 will negatively impact reported earnings in the short term. For traders, this represents a long-term positive as Perrigo refines its focus, but the near-term impairment could create volatility. The key opportunity lies in the market's reaction to the strategic clarity versus the immediate financial hit.